The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism
Objective. To evaluate cardiovascular risk, metabolic profile, low urinary tract symptoms (LUTS), and sexual function in patients with nonfunctional pituitary macroadenoma (NFPMA) and hypogonadotropic hypogonadism with testosterone therapy (TTh). Methods. A retrospective clinical study at a tertiary...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/2356580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467729529012224 |
|---|---|
| author | Guadalupe Vargas-Ortega Gabriel Pérez-Villarreal Andrés Ramírez de Santiago Lourdes Balcázar-Hernández Victoria Mendoza-Zubieta Oscar Landa-Gutierrez Carlos Estrada-Robles Baldomero González-Virla |
| author_facet | Guadalupe Vargas-Ortega Gabriel Pérez-Villarreal Andrés Ramírez de Santiago Lourdes Balcázar-Hernández Victoria Mendoza-Zubieta Oscar Landa-Gutierrez Carlos Estrada-Robles Baldomero González-Virla |
| author_sort | Guadalupe Vargas-Ortega |
| collection | DOAJ |
| description | Objective. To evaluate cardiovascular risk, metabolic profile, low urinary tract symptoms (LUTS), and sexual function in patients with nonfunctional pituitary macroadenoma (NFPMA) and hypogonadotropic hypogonadism with testosterone therapy (TTh). Methods. A retrospective clinical study at a tertiary care center was performed in 101 men with NFPMA, HH, and TTh; metabolic profile, cardiovascular risk, International Prostate Symptoms Score (IPSS), and International Index of Erectile Function 5 (IIEF-5) scores were evaluated before initiation of TTh and at the last checkup with TTh. Results. Age was 49.3 ± 8.8 years; T before TTh was 195 ng/mL (101–259) vs. 574 (423–774) at the last checkup. The time of TTh administration was 34 months (12–72). An increase in triglyceride levels (200 (153–294) vs. 174 (134–233) mg/dL; p=0.03), dyslipidemia (40% vs. 52%; p=0.03), and MetS (25% vs. 34%; p=0.05) was corroborated. A statistical difference in the Globorisk score and cardiovascular (CV) risk stratification was not found. IIEF-5 score was 15.5 ± 6.5 vs. 17.8 ± 5.3 (p=0.11). An improvement in penetration quality (2.0 ± 1.5 vs. 2.6 ± 1.3; p=0.05), erection after penetration (1.8 ± 1.2 vs. 2.5 ± 1.6; p=0.02), completion of intercourse (1.8 ± 1.2 vs. 2.4 ± 1.3; p=0.03), and satisfaction of sexual intercourse (1.8 ± 1.3 vs. 2.5 ± 1.5; p=0.01) was evidenced. IPSS score was 6 (IQR 2–10) vs. 7 (IQR 4–12); p=0.30. A lower rate of intermittency (14% vs. 3%; p=0.02), urgency (39% vs. 16%; p=0.01), and episodes of nocturia (18% vs. 4%; p=0.02) was found. An increase of hematocrit (44.1 ± 4.4 vs. 47.3 ± 4.4%; p=0.001), hemoglobin (14.9 ± 1.4 vs. 15.9 ± 1.4 g/dL; p=0.001), and prostatic specific antigen (0.59 (0.43–1.19) vs. 0.82 (0.45–1.4) ng/mL; p=0.02) was evidenced during TTh. Conclusion. TTh in young men with NFPMA improves LUTS, sexual function, and some metabolic parameters, and it is relatively safe in the prostatic context. |
| format | Article |
| id | doaj-art-e0625abaa487421cbbf1f1a736b07a00 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-e0625abaa487421cbbf1f1a736b07a002025-08-20T03:26:05ZengWileyInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/23565802356580The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic HypogonadismGuadalupe Vargas-Ortega0Gabriel Pérez-Villarreal1Andrés Ramírez de Santiago2Lourdes Balcázar-Hernández3Victoria Mendoza-Zubieta4Oscar Landa-Gutierrez5Carlos Estrada-Robles6Baldomero González-Virla7From the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoFrom the Endocrinology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, MexicoObjective. To evaluate cardiovascular risk, metabolic profile, low urinary tract symptoms (LUTS), and sexual function in patients with nonfunctional pituitary macroadenoma (NFPMA) and hypogonadotropic hypogonadism with testosterone therapy (TTh). Methods. A retrospective clinical study at a tertiary care center was performed in 101 men with NFPMA, HH, and TTh; metabolic profile, cardiovascular risk, International Prostate Symptoms Score (IPSS), and International Index of Erectile Function 5 (IIEF-5) scores were evaluated before initiation of TTh and at the last checkup with TTh. Results. Age was 49.3 ± 8.8 years; T before TTh was 195 ng/mL (101–259) vs. 574 (423–774) at the last checkup. The time of TTh administration was 34 months (12–72). An increase in triglyceride levels (200 (153–294) vs. 174 (134–233) mg/dL; p=0.03), dyslipidemia (40% vs. 52%; p=0.03), and MetS (25% vs. 34%; p=0.05) was corroborated. A statistical difference in the Globorisk score and cardiovascular (CV) risk stratification was not found. IIEF-5 score was 15.5 ± 6.5 vs. 17.8 ± 5.3 (p=0.11). An improvement in penetration quality (2.0 ± 1.5 vs. 2.6 ± 1.3; p=0.05), erection after penetration (1.8 ± 1.2 vs. 2.5 ± 1.6; p=0.02), completion of intercourse (1.8 ± 1.2 vs. 2.4 ± 1.3; p=0.03), and satisfaction of sexual intercourse (1.8 ± 1.3 vs. 2.5 ± 1.5; p=0.01) was evidenced. IPSS score was 6 (IQR 2–10) vs. 7 (IQR 4–12); p=0.30. A lower rate of intermittency (14% vs. 3%; p=0.02), urgency (39% vs. 16%; p=0.01), and episodes of nocturia (18% vs. 4%; p=0.02) was found. An increase of hematocrit (44.1 ± 4.4 vs. 47.3 ± 4.4%; p=0.001), hemoglobin (14.9 ± 1.4 vs. 15.9 ± 1.4 g/dL; p=0.001), and prostatic specific antigen (0.59 (0.43–1.19) vs. 0.82 (0.45–1.4) ng/mL; p=0.02) was evidenced during TTh. Conclusion. TTh in young men with NFPMA improves LUTS, sexual function, and some metabolic parameters, and it is relatively safe in the prostatic context.http://dx.doi.org/10.1155/2019/2356580 |
| spellingShingle | Guadalupe Vargas-Ortega Gabriel Pérez-Villarreal Andrés Ramírez de Santiago Lourdes Balcázar-Hernández Victoria Mendoza-Zubieta Oscar Landa-Gutierrez Carlos Estrada-Robles Baldomero González-Virla The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism International Journal of Endocrinology |
| title | The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism |
| title_full | The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism |
| title_fullStr | The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism |
| title_full_unstemmed | The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism |
| title_short | The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism |
| title_sort | testosterone effect on metabolic and urologic outcomes in patients with nonfunctioning pituitary macroadenomas and hypogonadotropic hypogonadism |
| url | http://dx.doi.org/10.1155/2019/2356580 |
| work_keys_str_mv | AT guadalupevargasortega thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT gabrielperezvillarreal thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT andresramirezdesantiago thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT lourdesbalcazarhernandez thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT victoriamendozazubieta thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT oscarlandagutierrez thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT carlosestradarobles thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT baldomerogonzalezvirla thetestosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT guadalupevargasortega testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT gabrielperezvillarreal testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT andresramirezdesantiago testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT lourdesbalcazarhernandez testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT victoriamendozazubieta testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT oscarlandagutierrez testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT carlosestradarobles testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism AT baldomerogonzalezvirla testosteroneeffectonmetabolicandurologicoutcomesinpatientswithnonfunctioningpituitarymacroadenomasandhypogonadotropichypogonadism |